Jointly developed by Biogen and Sage Therapeutics, the oral drug, Zurzuvae (zuranolone), offers a significant advancement in postpartum depression (PPD) treatment options.
PPD is a form of major depressive episode occurring after childbirth or even during the later stages of pregnancy. The previous treatment for PPD was available solely as an intravenous injection administered by healthcare professionals in specific healthcare facilities, as noted by the FDA.